0
0
Home » Pharmaceuticals » Therapy Area » Oncology

Neuroendocrine Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

The Neuroendocrine Tumors Drugs in Development market research report provides an overview of the Neuroendocrine tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine tumors and features dormant and discontinued projects.

What are the targets of the Neuroendocrine tumors pipeline drugs market?

Some of the targets of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2, Somatostatin Receptor, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Programmed Cell Death Protein 1, Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2, Receptor Type Tyrosine Protein Kinase FLT3, Somatostatin Receptor Type 5, and Cells Expressing Somatostatin Receptor.

Neuroendocrine tumors pipeline drugs market, by targets

Neuroendocrine tumors pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Neuroendocrine tumors pipeline drugs market?

Some of the mechanisms of action of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Somatostatin Receptor Agonist, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2 Agonist, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Somatostatin Receptor Type 5 Agonist, and Cytotoxic To Cells Expressing Somatostatin Receptor.

Neuroendocrine tumors pipeline drugs market, by mechanisms of action

Neuroendocrine tumors pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Neuroendocrine tumors pipeline drugs market?

Some of the routes of administration in the Neuroendocrine tumors pipeline drugs market are oral, intravenous, subcutaneous, intravenous drip, intraarterial, intratumor, intrahepatic, intralesional, intramuscular, and intravesical.

Neuroendocrine tumors pipeline drugs market, by routes of administration

Neuroendocrine tumors pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Neuroendocrine tumors pipeline drugs market?

The molecule types in the Neuroendocrine tumors pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, oncolytic virus, peptide, cell therapy, gene-modified cell therapy, vaccine, biologic, and monoclonal antibody conjugated.

Neuroendocrine tumors pipeline drugs market, by molecule types

The molecule types in the Neuroendocrine tumors pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, oncolytic virus, peptide, cell therapy, gene-modified cell therapy, vaccine, biologic, and monoclonal antibody conjugated.   Neuroendocrine tumors pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Neuroendocrine tumors pipeline drugs market?

Some of the key companies in the Neuroendocrine tumors pipeline drugs market are Ipsen SA, Exelixis Inc, Hutchison MediPharma Ltd, Pfizer Inc, Advanced Accelerator Applications SA, ASCIL Biopharm, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, and Chimerix Inc.

Neuroendocrine tumors pipeline drugs market, by key companies

Neuroendocrine tumors pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Vascular Endothelial Growth Factor Receptor 2, Somatostatin Receptor, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Programmed Cell Death Protein 1, Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2, Receptor Type Tyrosine Protein Kinase FLT3, Somatostatin Receptor Type 5, and Cells Expressing Somatostatin Receptor
Mechanisms of Action Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Somatostatin Receptor Agonist, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2 Agonist, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Somatostatin Receptor Type 5 Agonist, and Cytotoxic To Cells Expressing Somatostatin Receptor
Routes of Administration Oral, Intravenous, Subcutaneous, Intravenous Drip, Intraarterial, Intratumor, Intrahepatic, Intralesional, Intramuscular, and Intravesical
Molecule Types Small Molecule, Monoclonal Antibody, Synthetic Peptide, Oncolytic Virus, Peptide, Cell Therapy, Gene-Modified Cell Therapy, Vaccine, Biologic, and Monoclonal Antibody Conjugated
Key Companies Ipsen SA, Exelixis Inc, Hutchison MediPharma Ltd, Pfizer Inc, Advanced Accelerator Applications SA, ASCIL Biopharm, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, and Chimerix Inc

This report provides:

  • A snapshot of the global therapeutic landscape of Neuroendocrine tumors.
  • Reviews of pipeline therapeutics for Neuroendocrine tumors by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key players involved in Neuroendocrine tumors therapeutics and enlists all their major and minor projects.
  • Assessment of Neuroendocrine tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Neuroendocrine tumors.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Neuroendocrine tumors.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Neuroendocrine tumors pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Players

Aadi Bioscience Inc

Advanced Accelerator Applications SA

Advenchen Laboratories LLC

Akeso Inc

Alphamab Oncology

Amphivena Therapeutics Inc

Amryt Pharma Plc

AnHeart Therapeutics Inc

Aquestive Therapeutics Inc

Ascentage Pharma Group International

ASCIL Biopharm

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Beijing Foreland Pharma Co Ltd

Boehringer Ingelheim International GmbH

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Camurus AB

CanBas Co Ltd

Chimeric Therapeutics Ltd

Chimerix Inc

Clarity Pharmaceuticals Pty Ltd

Crinetics Pharmaceuticals Inc

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Eisai Co Ltd

Eli Lilly and Co

Elicera Therapeutics AB

Enterome Bioscience SA

EpicentRx Inc

Esanex Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

GlaxoSmithKline Plc

Harbour BioMed (Guangzhou) Co Ltd

Harpoon Therapeutics Inc

HEC Pharma Co Ltd

Hutchison MediPharma Ltd

Imagine Pharma LLC

Immunwork Inc

Innovent Biologics Inc

Inspirna Inc

INVENT Pharmaceuticals Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Jubilant DraxImage Inc

Jubilant Therapeutics Inc

Karyopharm Therapeutics Inc

Lixte Biotechnology Holdings Inc

Merck & Co Inc

Merck KGaA

MimiVax LLC

Mina Therapeutics Ltd

Molecular Targeting Technologies Inc

Molecular Templates Inc

NanoValent Pharmaceuticals Inc

Northwest Biotherapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Orano Med LLC

Pfizer Inc

Pharma Mar SA

Pharmathen Global BV

POINT Biopharma Global Inc

PRISM Pharma Co Ltd

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Rani Therapeutics LLC

Regulaxis SAS

Seneca Therapeutics Inc

Shanghai Junshi Bioscience Co Ltd

Shenzhen Chipscreen Biosciences Co Ltd

Sichuan Huiyang Life Science and Technology Corp

Strongbridge Biopharma plc

Suntec Medical (Taiwan) Inc

Taiho Oncology Inc

Tarveda Therapeutics Inc

Teclison Ltd

TerSera Therapeutics LLC

Tmunity Therapeutics Inc

Trio Medicines Ltd

Vanquish Oncology Inc

Viewpoint Molecular Targeting LLC

Vyriad Inc

Xencor Inc

Y-Biologics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuroendocrine Tumors – Overview

Neuroendocrine Tumors – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neuroendocrine Tumors – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuroendocrine Tumors – Companies Involved in Therapeutics Development

Neuroendocrine Tumors – Drug Profiles

Neuroendocrine Tumors – Dormant Projects

Neuroendocrine Tumors – Discontinued Products

Neuroendocrine Tumors – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Neuroendocrine Tumors, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Neuroendocrine Tumors – Dormant Projects, 2021

Neuroendocrine Tumors – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Neuroendocrine Tumors, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

The targets of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2, Somatostatin Receptor, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Programmed Cell Death Protein 1, Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2, Receptor Type Tyrosine Protein Kinase FLT3, Somatostatin Receptor Type 5, and Cells Expressing Somatostatin Receptor.

Some of the mechanisms of action of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Somatostatin Receptor Agonist, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2 Agonist, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Somatostatin Receptor Type 5 Agonist, and Cytotoxic To Cells Expressing Somatostatin Receptor.

Some of the routes of administration in the Neuroendocrine tumors pipeline drugs market are oral, intravenous, subcutaneous, intravenous drip, intraarterial, intratumor, intrahepatic, intralesional, intramuscular, and intravesical.

The molecule types in the Neuroendocrine tumors pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, oncolytic virus, peptide, cell therapy, gene-modified cell therapy, vaccine, biologic, and monoclonal antibody conjugated.

Some of the key companies in the Neuroendocrine tumors pipeline drugs market are Ipsen SA, Exelixis Inc, Hutchison MediPharma Ltd, Pfizer Inc, Advanced Accelerator Applications SA, ASCIL Biopharm, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, and Chimerix Inc.

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports